{"links":{"html":"https://www.erudio.com/reports/temab-a-nct05029882","json":"https://www.erudio.com/reports/temab-a-nct05029882.json","markdown":"https://www.erudio.com/reports/temab-a-nct05029882.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"temab-a-05029882"}},"request":"https://www.erudio.com/contact?report=temab-a-05029882"},"offer":{"cited_commentary_sources":27,"verified_hcp_statements":70,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":17,"optional":true,"price_per_verified_person_usd":15,"price_usd":255,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"temab-a-nct05029882"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=temab-a-05029882","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/temab-a-nct05029882","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T03:01:37.141236Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the sample findings; source quotations and links in the paid report. An editorial bracket follows a transcription-garbled trial name in quotations: “Tenmab [Temab]”. The trial's registration date is now stated."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":13,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":15,"title":"Primary endpoint: Objective Response Rate (ORR)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":3,"title":"Secondary endpoint: Duration of Response (DOR) for Participants with Confirmed CR/PR per RECIST v1.1"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":10,"title":"Secondary endpoint: PFS per RECIST v1.1"},{"claim_count":10,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":11,"title":"Secondary endpoint: Overall survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":0,"title":"Secondary endpoint: Parts 1-6: ORR per Independent Central Review (ICR) in Participants with MET Amplification"},{"claim_count":13,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":14,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":10,"title":"The comparison"},{"claim_count":11,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.interventions","source_count":11,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":1,"coverage":"discussed","id":"A1","source_count":1,"title":"Dose optimization versus maximum tolerated dose"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":11,"title":"c-Met protein expression and exploratory patient selection"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Patient navigation and toxicity-support implications"},{"claim_count":12,"coverage":"discussed","id":"A4","source_count":2,"title":"Regulatory significance, unmet need and development expectations"},{"claim_count":8,"coverage":"discussed","id":"A5","source_count":5,"title":"Payload rationale and unanswered ADC or chemotherapy comparisons"}],"counts":{"cited_sources":29,"claims_by_expression_type":{"comparison":7,"experience":1,"interpretation":27,"opinion":9,"primary_context":6,"question":6,"restatement":10,"uncertainty":3,"unspecified":1},"claims_by_kind":{"attributed_opinion":17,"objective_result":3,"protocol_statement":2,"publication_statement":20,"source_observation":28},"clinician_statements":17,"evidence_units":72,"findings":7,"organisational_accounts":4,"people_cited":18,"people_identity_verified":17,"people_total":18,"screened_sources":53,"verified_claims":70},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":1,"views":2},"has_counterview":true,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"In pretreated EGFR-mutant NSCLC, activity does not settle the tolerability question"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":6},"has_counterview":true,"limitations":4,"links":{"context":0,"support":9},"ma_question":true,"named_voices":3,"passages":9,"sources":7,"sources_by_kind":{"commentary":6,"publication":1}},"title":"The colorectal combination signal attracts enthusiasm, with survival certainty explicitly challenged"},{"id":"F3","structure":{"claims":16,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":4,"views":9},"has_counterview":true,"limitations":4,"links":{"context":2,"support":16},"ma_question":true,"named_voices":6,"passages":14,"sources":7,"sources_by_kind":{"commentary":6,"publication":1}},"title":"Late-line colorectal monotherapy interest rests on dose optimization and response enrichment, not a validated selection rule"},{"id":"F4","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":5,"views":2},"has_counterview":false,"limitations":5,"links":{"context":1,"support":14},"ma_question":true,"named_voices":7,"passages":12,"sources":10,"sources_by_kind":{"commentary":10}},"title":"NSCLC commentary raises subgroup, payload and sequencing questions rather than proving ADC superiority"},{"id":"F5","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Patient-support commentary connects treatment continuation with proactive toxicity navigation"},{"id":"F6","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":3,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"The gastroesophageal interview offers a qualified, setting-specific activity and tolerability reading"},{"id":"F7","structure":{"claims":17,"claims_by_group":{"comparisons":2,"experience":0,"questions":2,"restated":2,"views":11},"has_counterview":true,"limitations":3,"links":{"context":0,"support":18},"ma_question":true,"named_voices":1,"passages":7,"sources":3,"sources_by_kind":{"commentary":1,"media":1,"publication":1}},"title":"Regulatory and mechanistic enthusiasm extends beyond what the early clinical evidence establishes"}],"medical_affairs_question":"How should Medical Affairs explain activity, cohort-specific biomarkers and dose trade-offs without overstating tolerability, survival certainty or regulatory significance?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Activity and tolerability are separate judgments in EGFR-mutant NSCLC"},{"id":"section-2","level":2,"title":"The colorectal combination is promising, but the OS interpretation remains provisional"},{"id":"section-3","level":2,"title":"Colorectal monotherapy interest is conditional on dose and biomarker interpretation"},{"id":"section-4","level":2,"title":"Lung-cancer subgroup observations generate questions about payload and treatment partners"},{"id":"section-5","level":2,"title":"Supportive care is proposed as an aid to navigation, not ILD prevention"},{"id":"section-6","level":2,"title":"The gastroesophageal interpretation remains cohort-specific"},{"id":"section-7","level":2,"title":"Regulatory enthusiasm and mechanistic promise are not clinical confirmation"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, sequential, phase1","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":1}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T2","label":"Secondary endpoint: Duration of Response (DOR) for Participants with Confirmed CR/PR per RECIST v1.1"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T3","label":"Secondary endpoint: PFS per RECIST v1.1"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3}],"id":"T4","label":"Secondary endpoint: Overall survival (OS)"},{"findings":[],"id":"T5","label":"Secondary endpoint: Parts 1-6: ORR per Independent Central Review (ICR) in Participants with MET Amplification"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":6},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":2}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":5},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":2}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T03:01:37.141236Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T05:55:03Z","record_hash":"3782f054f310859fa69f981cd09b8a42a97630d4dec434543dde7b1054fe9137","release_hash":"f89b51cc96f14587c566498cdaa82af5a95ae38610ecedd2701b247c3ceaed67","report_id":"erudio-nct05029882","run_id":"3f7f9c6f-73ae-4c0e-8ac6-ac9390975f0e","schema_version":"5.0","slug":"temab-a-05029882","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Temab-A examines activity and tolerability of a c-Met–targeted antibody–drug conjugate, alone or with bevacizumab, in previously treated advanced solid cancers. X posters welcome the colorectal combination signal, while one poster questions survival certainty. In pretreated EGFR-mutant lung cancer, one physician welcomes response activity, but two physicians question tolerability. Two physicians pose unresolved questions about payload differences and comparisons with other antibody–drug conjugates.","meta_description":"53 sources screened · 70 verified statements (17 from clinicians verified by NPI or staff page) from 29 sources · 7 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-822f7a554567970fb338"],"id":"F1","paraphrase":"A physician posting on X asks how treatment tolerability should be described for Temab-A in previously treated EGFR-mutant lung cancer.","source_channel":"x_thread","source_date":"2025-06-02","title":"In pretreated EGFR-mutant NSCLC, activity does not settle the tolerability question"},{"cited_claim_ids":["claim-9c40c5dac1b1e707a4fa","claim-c1e50a031e2529f3a9e1"],"id":"F4","paraphrase":"Two physicians in an X exchange ask whether payload changes affect outcomes and how Temab-A compares with Teliso-V in nonsquamous lung cancer.","source_channel":"x_thread","source_date":"2026-10-24","title":"NSCLC commentary raises subgroup, payload and sequencing questions rather than proving ADC superiority"}]},"publication":{"approved_at":"2026-10-29T05:55:03Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T06:12:11Z","summary":"Corrected to match the delivered report: the sample findings; source quotations and links in the paid report. An editorial bracket follows a transcription-garbled trial name in quotations: “Tenmab [Temab]”. The trial's registration date is now stated."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":53},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","33 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are not a representative survey of HCPs. Repeated posts, presentation relays, organizational voices and authors without established clinical roles cannot be counted as independent clinician endorsements.","Fifty-nine potentially relevant sources that did not name the trial were not read, and several passages were not fully assessed. Additional views on the same clinical decisions may therefore be absent.","Different tumor types, molecular subgroups, doses, regimens and reporting times are represented. Their results and tolerability judgments cannot be pooled or used to infer a change of mind.","The NSCLC discontinuation figures have different descriptions, and a speaker’s quoted drug naming remains inconsistent. The report does not resolve those differences.","The sources use both AndroMETa-560 and AndroMETa-CRC; no equivalence between those names is assumed.","A full protocol and exact regulatory labels for ABBV-400 and trifluridine/tipiracil were not available. Regulatory designations and investigational status are reported as attributed in the sources, not as an independently assessed approval determination.","Retrospective biomarker analyses, mixed tissue timing, small comparison groups and wide survival intervals limit conclusions about selection, superiority and future treatment positioning."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":24,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":27,"context":1,"results":1},"count":29,"evidence_window":{"end":"2026-10-26","start":"2024-06-03"},"retrieval_snapshot":"2026-10-28T21:56:56.320953Z","timeline":[{"count":3,"week":"2024-W23"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":5,"week":"2025-W23"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2026-W18"},{"count":2,"week":"2026-W19"},{"count":2,"week":"2026-W41"},{"count":8,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05029882:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05029882:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42066233","quote_policy":"no_derivatives"},{"id":"pubmed:42926107","quote_policy":"short_quote_link_out"},{"id":"openfda:4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe:20260821","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-2fykzdsl6dmpn5q3u2ew3gkn-3mysbtih7lc2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3m3mdcthkfc22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mxluwyccjs2a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797710446411354297:fb018360-3392-48ca-a711-341fff36c321","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797710489180643340:97df5b14-cb6f-4adc-a8e0-2b54ace5f8c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797710796518232245:77c6503b-3ec2-4e4a-ba06-489a0a51b989","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797710933713879143:211fa21b-ab85-43ef-bbd8-0a57422e1c41","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806766671862054983:d593258b-ada3-463c-9ee5-10bc6875480b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1833284303754780756:553a4657-7dc5-4689-a940-1aa9636bab16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1834937926381162731:ea6679bd-871b-43ec-ad20-5ae852154a8d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835341099642351781:638e833c-5c33-4652-957a-970b61bddd78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925898330464301489:3371a30d-34f2-4b49-81ef-f16e24a4bafc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926682757570154889:7568b15f-0aff-47b0-99f6-29e7aeb263dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928301870189269132:2938f22f-3fcf-40e0-8660-861be7d4caf0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929525216255819960:b2c308cb-0b0d-4fa4-bf51-9871279978da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929525234274599105:67445743-8d9e-456d-840b-d3254c832f57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929526290177982490:8d38856a-5ec1-4711-bfd3-616206a5ba0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929527028723691537:243b3fcb-6a3e-4b2b-97b8-09906595c3a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931379101073637580:814c9f74-5164-42c2-9f7b-4871966b24c4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979908677977911691:737c2b29-c55b-4127-89d5-e25088317fd6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050524888629428719:c3a025de-51dd-4c5b-a607-6439883b6c48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050573666572788183:79ea9d19-1f11-4081-807c-900da47b9546","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051401921051713722:4f71413c-77d0-4806-b3bc-d3f2648dea56","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051602906944594080:e65087ee-d173-40e0-81c4-e6797eb45b5b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053030843912794397:bcb7fa39-a760-4147-b534-08a8a20b7799","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057142128560796037:e5b98083-4b50-42a6-b7eb-8ddc46d2614b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059753941043196079:d01b39a0-00e7-47ad-8a63-9e7e890eacb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065056508182692319:99a98976-776d-4e1c-ba92-cf3c4c97a16f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066282191773192608:ee5bed42-92f0-440e-8bee-7e49997f8f14","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2074964436285297100:c41e10fd-04c2-4fa8-b83f-fc66288d51f2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095765603302961188:5653d772-7663-436e-9363-43fbb61658a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107811522202239219:1b9d8564-1a6c-426f-a659-509a15226ef2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107819948659904722:60ebca73-1dce-4ee2-a4db-497a0312d900","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107900152371654716:04dd0697-bb63-45c2-a03a-5050d04a7f4c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107960816041603305:ec300cc4-f981-4ca4-83d1-34767569c0f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112891653380075755:035904f3-4175-410f-8419-9bb0b7c30071","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113899546254389469:8fb66959-e3ac-4461-96d2-511ebf1b106c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113899551618637853:480edff4-8824-4740-b205-9b322b870309","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113963726378533013:47abccbb-73d0-43ff-a971-94b5d880e55f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113975041239220234:ab5f881f-b587-4914-ae22-8a1a11b64488","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113980029235536367:ea6af600-25b4-4b86-89fe-25dadd5268e7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986144325263483:5fbc691c-2579-43f5-b238-b79092e38c76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986368732881355:201f98d9-c494-49ca-95cd-5b9353d1eacc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986664724873349:83e34e2d-ae15-44ef-9d17-8767d89ad850","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113986916626637146:d05f430b-f36a-4e37-b698-9ce0be9dbc12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113987609596756313:a717d085-a63e-4d29-aceb-95c549923375","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113988114431529179:b288f5d1-79c3-497c-b856-684c6191a94c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113991829758586887:37c9be60-68fe-4b4a-af08-cc967ae5ef34","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114017250684649693:94d21730-a9fe-4403-8c58-8544b39bfcbb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114245263640416740:d5617364-37dc-431b-9c09-df5f16997b05","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114673398710427941:411d0a17-db72-46ef-bf9c-7756b36469c7","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:RlYffX5ExYo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:rRS_ifw0_AU","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":48,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":53},"count":53,"evidence_window":{"end":"2026-10-26","start":"2024-06-03"},"retrieval_snapshot":"2026-10-28T21:56:56.320953Z","timeline":[{"count":4,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W44"},{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":5,"week":"2025-W23"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":2,"week":"2026-W18"},{"count":3,"week":"2026-W19"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W28"},{"count":1,"week":"2026-W36"},{"count":6,"week":"2026-W41"},{"count":15,"week":"2026-W43"},{"count":2,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: abbv-400","status":"unmapped"},{"brand_names":["Lonsurf"],"label":"trifluridine/tipiracil","slug":"trifluridine-tipiracil"},{"brand_names":["Avastin"],"label":"bevacizumab","slug":"bevacizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"},{"reason":"Unmapped registry condition: Gastroesophageal Adenocarcinoma","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"Temab-A","aliases":["Temab-A","M21-404","Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors"],"brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer","Advanced Solid Tumors","Gastroesophageal Adenocarcinoma","Colorectal Cancer"],"enrollment":{"count":520,"type":"ACTUAL"},"interventions":[{"name":"ABBV-400","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Trifluridine/Tipiracil","synonyms":["TAS-102"],"type":"DRUG"},{"name":"Bevacizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05029882","official_title":"A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"ORR defined as percentage of participants with confirmed best overall response of Confirmed complete response (CR) and partial response (PR) per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","measure":"Objective Response Rate (ORR)","timeFrame":"Up to 48 Months"}],"registered_date":{"date":"2021-09-01","type":"ACTUAL"},"registry_last_updated":"2025-10-29","registry_url":"https://clinicaltrials.gov/study/NCT05029882","short_name":"Temab-A","short_name_basis":"canonical_name","sponsor":"AbbVie","start_date":{"date":"2021-10-13","type":"ACTUAL"},"study_design":"interventional, non randomized, sequential, phase1","study_ids":[{"id":"M21-404","type":"sponsor_study_id"},{"domain":"EU CT","id":"2023-509335-60-00","type":"other"}],"study_type":"INTERVENTIONAL"}}}